Johnson & Johnson / 强生

Johnson & Johnson appears in E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学 through its collaboration with Legend Biotech / 南京传奇 on a multiple-myeloma [[CARTCellTherapy|CAR-T]] product. The source uses that partnership as a commercialization example rather than as a broad company profile.

In the episode, the Legend-Johnson & Johnson case supports the claim that ex vivo CAR-T can become a major drug business in blood cancers even while manufacturing remains expensive. It also shows why big pharma interest in In Vivo CAR-T is commercially legible: if CAR-T efficacy is strong but Ex Vivo CAR-T Manufacturing is the bottleneck, moving manufacturing into the patient could expand access and margins.

Key Claims

• Johnson & Johnson is linked to a CAR-T commercial success case in multiple myeloma.
• The source uses the case to show treatment-line movement: strong efficacy can push a product from late-line use toward earlier-line therapy.
• The company is part of the episode’s broader big-pharma context around oncology cell therapy.

Connections

• Legend Biotech / 南京传奇 - partner and Chinese biotech commercialization case.
• CAR-T Cell Therapy and Ex Vivo CAR-T Manufacturing - therapy route behind the source’s commercial example.
• In Vivo CAR-T - adjacent route whose attractiveness is partly explained by ex vivo manufacturing costs.